A unique combination of heterozygous CFTR gene variants in a person with cystic fibrosis and M. abscessus infection.

IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM
Respiration Pub Date : 2025-03-28 DOI:10.1159/000545552
Arthur Lemson, Cedric Bosteels, Jakko van Ingen, Monique Reijers, Dineke Westra, Wouter Hoefsloot
{"title":"A unique combination of heterozygous CFTR gene variants in a person with cystic fibrosis and M. abscessus infection.","authors":"Arthur Lemson, Cedric Bosteels, Jakko van Ingen, Monique Reijers, Dineke Westra, Wouter Hoefsloot","doi":"10.1159/000545552","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene. A minority of people with CF carry two heterozygous CFTR mutations other than the common Phe508del, complicating diagnosis and treatment.</p><p><strong>Case presentation: </strong>We report the case of a 25-year-old South American male diagnosed with CF respiratory disease, characterized by a history of recurrent infections, pulmonary Mycobacterium abscessus infection, airway disease on high-resolution CT, and an elevated sweat chloride level (74 mmol/L). Exome sequencing identified a unique combination of CFTR mutations: a pathogenic frameshift variant (c.2052dup) and a variant of unknown clinical significance (c.710A>C). Notably, there were no signs of pancreatic insufficiency. Rectal mucosal organoid cultures demonstrated residual CFTR function with responsiveness to ivacaftor and the combination of elexacaftor, tezacaftor, and ivacaftor.</p><p><strong>Conclusion: </strong>This case highlights a unique combination of heterozygous CFTR variants in a person with late-onset CF respiratory disease, which may be amenable to CFTR modulation therapy.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-10"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiration","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545552","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene. A minority of people with CF carry two heterozygous CFTR mutations other than the common Phe508del, complicating diagnosis and treatment.

Case presentation: We report the case of a 25-year-old South American male diagnosed with CF respiratory disease, characterized by a history of recurrent infections, pulmonary Mycobacterium abscessus infection, airway disease on high-resolution CT, and an elevated sweat chloride level (74 mmol/L). Exome sequencing identified a unique combination of CFTR mutations: a pathogenic frameshift variant (c.2052dup) and a variant of unknown clinical significance (c.710A>C). Notably, there were no signs of pancreatic insufficiency. Rectal mucosal organoid cultures demonstrated residual CFTR function with responsiveness to ivacaftor and the combination of elexacaftor, tezacaftor, and ivacaftor.

Conclusion: This case highlights a unique combination of heterozygous CFTR variants in a person with late-onset CF respiratory disease, which may be amenable to CFTR modulation therapy.

囊性纤维化和脓肿分枝杆菌感染患者中杂合CFTR基因变异的独特组合。
简介:囊性纤维化(CF)是一种由CFTR基因突变引起的遗传性疾病。除常见的Phe508del外,少数CF患者携带两种杂合CFTR突变,使诊断和治疗复杂化。病例介绍:我们报告一例25岁的南美男性CF呼吸道疾病,其特征是反复感染史,肺脓肿分枝杆菌感染,高分辨率CT显示气道疾病,汗液氯化物水平升高(74 mmol/L)。外显子组测序鉴定出CFTR突变的独特组合:一种致病性移码变体(C .2052dup)和一种临床意义未知的变体(C . 710a >C)。值得注意的是,没有胰腺功能不全的迹象。直肠粘膜类器官培养显示残留的CFTR功能,对激活因子和elexaftor、tezacaftor和激活因子的组合有反应。结论:该病例突出了迟发性CF呼吸系统疾病患者中杂合CFTR变异的独特组合,可能适合CFTR调节治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respiration
Respiration 医学-呼吸系统
CiteScore
7.30
自引率
5.40%
发文量
82
审稿时长
4-8 weeks
期刊介绍: ''Respiration'' brings together the results of both clinical and experimental investigations on all aspects of the respiratory system in health and disease. Clinical improvements in the diagnosis and treatment of chest and lung diseases are covered, as are the latest findings in physiology, biochemistry, pathology, immunology and pharmacology. The journal includes classic features such as editorials that accompany original articles in clinical and basic science research, reviews and letters to the editor. Further sections are: Technical Notes, The Eye Catcher, What’s Your Diagnosis?, The Opinion Corner, New Drugs in Respiratory Medicine, New Insights from Clinical Practice and Guidelines. ''Respiration'' is the official journal of the Swiss Society for Pneumology (SGP) and also home to the European Association for Bronchology and Interventional Pulmonology (EABIP), which occupies a dedicated section on Interventional Pulmonology in the journal. This modern mix of different features and a stringent peer-review process by a dedicated editorial board make ''Respiration'' a complete guide to progress in thoracic medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信